Use of a taurolidine containing antimicrobial wash to reduce cardiac implantable electronic device infection
Open Access
- 5 October 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (10)
Abstract
TauroPace (Tauropharm, Bavaria Germany), a taurolidine solution for combating cardiac implantable electronic device (CIED) infection, was compared with a historical control of 3% hydrogen peroxide (H2O2) in a prospective observational study. The device pocket was irrigated, and all hardware accessible within (leads, suture sleeves, pulse generator) was wiped with H2O2, TauroPace, or taurolidine in a galenic formulation during any invasive CIED procedure at the study centre. Only CIED procedures covered by TauroPace or H2O2 from 1 January 2017 to 28 February 2022 were included for analysis. Patients who underwent >1 procedure were censored for the last treatment group and reassigned at the next procedure. The primary endpoint was major CIED infection within 3 months. The secondary endpoints were CIED infection beyond 3 months, adverse events potentially related to the antimicrobial solutions, CIED system, procedure, and death, till the end of follow-up. TauroPace covered 654 procedures on 631 patients, and H2O2 covered 551 procedures on 532 patients. The TauroPace group had more patient risk factors for infection than the H2O2 group (P = 0.0058) but similar device and procedure-specific risk factors (P = 0.17). Cardiac implantable electronic device infection occurred in 0/654 (0%) of the TauroPace group and 6/551 (1.1%) of the H2O2 group (P = 0.0075). Death occurred in 23/654 (3.5%) of the TauroPace group and 14/551 (2.5%) of the H2O2 group (P = 0.33). Non-infection related adverse events were rarer in the TauroPace (3.8%) than the H2O2 (6.0%) group (P = 0.0802). TauroPace is safe but more effective than H2O2 in reducing CIED infection. ClinicalTrials.gov Identifier: NCT05576194Keywords
Funding Information
- TauroPace™.
- TauroPace™
- TauroPace™.
- TauroPace™.
This publication has 65 references indexed in Scilit:
- Ultrasound description of Pecs II (modified Pecs I): A novel approach to breast surgeryRevista Española de Anestesiología y Reanimación, 2012
- Continued Rise in Rates of Cardiovascular Implantable Electronic Device Infections in the United States: Temporal Trends and Causative InsightsPacing and Clinical Electrophysiology, 2010
- Taurolidine Antiadhesive Properties on Interaction with E. coli; Its Transformation in Biological Environment and Interaction with Bacteria Cell WallPLOS ONE, 2010
- Prevalence of bacterial colonization of generator pockets in implantable cardioverter defibrillator patients without signs of infection undergoing generator replacement or lead revisionEP Europace, 2009
- Efficacy of Antibiotic Prophylaxis Before the Implantation of Pacemakers and Cardioverter-DefibrillatorsCirculation: Arrhythmia and Electrophysiology, 2009
- Using Detachment‐Promoting Agents for the Prevention of Chronic Peritoneal Dialysis‐Associated InfectionsArtificial Organs, 2008
- The Impact of Povidone‐Iodine Pocket Irrigation Use on Pacemaker and Defibrillator InfectionsPacing and Clinical Electrophysiology, 2005
- Sustained anti-adherence activity of taurolidine (Taurolin) and noxythiolin (Noxyflex S) solutionsJournal of Pharmacy and Pharmacology, 1988
- The Anti‐Endotoxin Activity of Taurolin in Experimental AnimalsJournal of Applied Bacteriology, 1979
- Taurolin, a New Chemotherapeutic AgentJournal of Applied Bacteriology, 1976